Pacira BioSciences Analyst Ratings
Truist Upgrades Pacira Biosciences to Hold From Sell, Boosts Price Target to $25 From $8
Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Raises Target Price to $50
Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)
RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target
Pacira BioSciences Analyst Ratings
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Raises Target Price to $30
Raymond James Maintains Pacira BioSciences(PCRX.US) With Hold Rating
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39
Pacira BioSciences Analyst Ratings
Pacira BioSciences Price Target Cut to $17.00/Share From $25.00 by Barclays
Pacira BioSciences Is Maintained at Equal-Weight by Barclays
Barclays Reaffirms Their Hold Rating on Pacira Pharmaceuticals (PCRX)
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $22
Pacira BioSciences Analyst Ratings
RBC Capital Adjusts Price Target on Pacira Biosciences to $16 From $15, Maintains Sector Perform Rating
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39